FREE Account Opening + No Clearing Fees
Loading...

Emcure Pharma IPO vs Stanley Lifestyles IPO

Comparision between Emcure Pharma IPO and Stanley Lifestyles IPO.

IPO Details

Emcure Pharma IPO is a Mainline Book Built Issue IPO proposed to list at BSE, NSE while Stanley Lifestyles IPO is a Mainline Book Built Issue proposed to list at BSE, NSE.

Issue Size and Price

The total issue size of Emcure Pharma IPO is whereas the issue size of the Stanley Lifestyles IPO is up to ₹537.02 Cr. The final issue price of Emcure Pharma IPO is and of Stanley Lifestyles IPO is ₹369.00 per share.

  Emcure Pharma IPO Stanley Lifestyles IPO
Face Value ₹10 per share ₹2 per share
Issue Price (Lower) ₹351.00 per share
Issue Price (Upper) ₹369.00 per share
Issue Price (Final) ₹369.00 per share
Discount (Retail)
Discount (Employee)
Market Lot Size 40 shares
Fresh Issue Size 54,20,054 shares
Fresh Issue Size (Amount) up to ₹800.00 Cr up to ₹200.00 Cr
OFS Issue Size 1,36,78,839 shares 91,33,454 shares
OFS Issue Size (Amount) up to ₹337.02 Cr
Issue Size Total 1,45,53,508 shares
Issue Size Total (Amount) up to ₹537.02 Cr

IPO Timetable

Emcure Pharma IPO opens on , while Stanley Lifestyles IPO opens on Jun 21, 2024. The closing date of Emcure Pharma IPO and Stanley Lifestyles IPO is , and Jun 25, 2024, respectively.

  Emcure Pharma IPO Stanley Lifestyles IPO
Anchor Bid Date Jun 20, 2024
Issue Open Jun 21, 2024
Issue Close Jun 25, 2024
Basis Of Allotment (Tentative) Jun 26, 2024
Initiation of Refunds (Tentative) Jun 27, 2024
Credit of Share (Tentative) Jun 27, 2024
Listing date (Tentative) Jun 28, 2024
Anchor Lockin End date 1 Jul 26, 2024
Anchor Lockin End date 2 Sep 24, 2024

Financials

Emcure Pharma IPO P/E ratio is , as compared to Stanley Lifestyles IPO P/E ratio of 54.43.

  Emcure Pharma IPO Stanley Lifestyles IPO
Financial
Summary of financial Information (Restated Consolidated)
Particulars For the year/period ended (₹ in Millions)
  31-March-21 31-March-20 31-March-19
Total Assets 68,073.98 60,040.55 58,104.39
Total Revenue 60,918.06 51,308.60 48,155.90
Profit After Tax 4,185.94 1,006.10 2,029.68

Stanley Lifestyles Limited Financial Information (Restated Consolidated)

Stanley Lifestyles Limited's revenue increased by 42.94% and profit after tax (PAT) rose by 50.64% between the financial year ending with March 31, 2023 and March 31, 2022.

Period Ended31 Dec 202331 Mar 202331 Mar 202231 Mar 2021
Assets581.54458.19422.15346.52
Revenue322.29425.62297.76201.71
Profit After Tax18.7034.9823.221.92
Net Worth237.21216.50199.76182.93
Reserves and Surplus225.83207.88191.31174.96
Total Borrowing30.909.376.090.25
Amount in ₹ Crore
Promoter Shareholding (Pre-Issue) 67.36%
Promoter Shareholding (Post-Issue) 56.81%
P/E Ratio 54.43
Market Cap ₹2103.94 Cr.
ROE 7.92%%
ROCE 8.63%%
Debt/Equity 0.86
EPS ₹6.78
RoNW 8.34%%

Shares Offered

In the Emcure Pharma IPO retail investors (RII) are offered while in Stanley Lifestyles IPO retail investors are offered . Qualified institutional buyers (QIB) are offered in Emcure Pharma IPO and 29,10,702 shares in Stanley Lifestyles IPO.

  Emcure Pharma IPO Stanley Lifestyles IPO
Anchor Investor Reserveration 43,66,051 shares
Market Maker Reserveration
QIB 29,10,702 shares
NII 21,83,026 shares
RII 50,93,728 shares
Employee 0 shares
Others
Total 1,01,87,456 shares

Bids Received (Subscription)

Emcure Pharma IPO subscribed in total, whereas Stanley Lifestyles IPO subscribed 97.16x.

  Emcure Pharma IPO Stanley Lifestyles IPO
QIB (times) 215.62x
NII (times) 121.42x
Big NII (times) 136.75x
Small NII (times) 90.76x
RII (times) 19.08x
Employee (times)
Other (times)
Total (times) 97.16x

Comments

Add a public comment...